Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 6/20 | 0.65 |
| ▸ | PNMT | P11086 | 2/20 | 0.59 |
| ▸ | CD44 | P16070 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4892220 | 0.93 | PNMT (0.66) | ASIC3PNMTCD44MAOBCD274 | |
| SCHEMBL30593253 | 0.93 | PNMT (0.59) | ASIC3PNMTCD44MAOBDRD2 | |
| SCHEMBL4663734 | 0.93 | PNMT (0.59) | ASIC3PNMTCD44MAOBDRD2 | |
| SCHEMBL8676339 | 0.84 | TYRO3 (0.50) | ASIC3PNMTCD44MAOBCD274 | |
| SCHEMBL29543554 | 0.84 | TYRO3 (0.50) | ASIC3PNMTCD44MAOBCD274 | |
| Biphenyl SCHEMBL27799394 | 0.84 | PNMT (0.83) | ASIC3PNMTCD44MAOBPRCP | |
| SCHEMBL28274279 | 0.84 | ASIC3 (0.63) | ASIC3PNMTCD44MAOBCD274 | |
| SCHEMBL8323150 | 0.84 | ASIC3 (0.78) | ASIC3PNMTCD44MAOBCD274 | |
| Hydrochloric Acid SCHEMBL7807038 | 0.82 | ASIC3 (0.76) | ASIC3PNMTCD44MAOBCD274 | |
| SCHEMBL1010614 | 0.82 | ASIC3 (0.61) | ASIC3PNMTCD44MAOBCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118742543-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-10-01 | — | — | CN | disclosed |
| CN-116789641-A | Dihydro isoquinoline compound and medical application thereof | 中国科学院上海药物研究所 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023174383-A1 | DIHYDROISOQUINOLINE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-09-21 | — | — | WO | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-6933306-B2 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LTD. (GB) | 2005-08-23 | — | — | US | disclosed |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-05-15 | — | — | US | disclosed |
| EP-1292576-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-6506773-B2 | For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration | DARWIN DISCOVERY LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-02-21 | — | — | US | disclosed |
| WO-2001087844-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| EP-0873317-B1 | PYRIMIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | EP | disclosed |
| EP-0687267-B1 | PYRROLO-PYRIDINE DERIVATIVES AS LIGANDS OF DOPAMINE RECEPTOR | MERCK SHARP & DOHME (GB) | 1999-09-01 | — | — | EP | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5700809-A | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
| US-5688798-A | PSYCHOTIC ILLNESS SUCH AS SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | ASIC3 4537/4885PNMT 3432/4885CD44 885/4885 |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | UACA, HCAR2, HCAR1 | ASIC3 46/4885PNMT 4831/4885CD44 219/4885 |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, HCAR3 | ASIC3 1750/4885PNMT 2044/4885CD44 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.